Arbutus Biopharma Corp to Discuss the Preliminary Phase 1a/1b Clinical Trial Results for AB-729 Conference Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Arbutus AB-729 Clinical Update Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions) I would now like to hand the conference over to your speaker today, Pam Murphy. Thank you, and please go ahead.
Good afternoon, everyone. Hopefully, you've been able to connect to the AB-729 clinical update webinar/webcast and that you are able to access the slides. With me today from the Arbutus executive team are Bill Collier, President and Chief Executive Officer; Dr. Gaston Picchio, Chief Development Officer; Dr. Mike Sofia, Chief Scientific Officer; and Dave Hastings, Chief Financial Officer.
Bill will begin with a quick summary of the data and planned next steps for 729. Gaston will then walk you through Parts 1 and 2 of the 3 part AB-729-001 Phase Ia/Ib clinical trial. We will then open up the call for Q&A after Gaston's presentation.
Before we begin, we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
